^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    felezonexor (CBS9106)

    i
    Other names: CBS9106, SL-801, CBC9106
    Company:
    CanBas, Menarini
    Drug class:
    XPO1 inhibitor
    Related drugs:
    almost4years
    [VIRTUAL] Updated results of a phase I study of Felezonexor (SL-801), a novel XPO-1 reversible inhibitor, in patients with relapsed/refractory solid tumours (ESMO 2020)
    Funding: Stemline Therapeutics, Inc. Clinical trial identification: NCT02667873.
    Clinical • P1 data • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • CCND1 (Cyclin D1) • BIRC5 (Baculoviral IAP repeat containing 5)
    |
    felezonexor (CBS9106)